NVision Imaging Technologies develops Quantum MRI agents that utilize hyperpolarization to enhance the visibility of metabolic agents in standard MRI scans, enabling rapid assessment of early patient response to cancer treatment at the cellular level. This technology provides critical insights into tumor activity and viability within minutes, allowing for timely adjustments in treatment strategies.
Funding
$55M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Conventional MRI struggles to detect early changes in cellular metabolism, limiting the ability to rapidly assess a patient's response to cancer treatment. Current methods often only reveal changes at the tissue level, which can take months to become apparent. This delay hinders timely adjustments to treatment strategies.
Solution
NVision Imaging Technologies provides a quantum-based platform that enhances metabolic agent visibility in standard MRI scans, enabling the use of metabolic MRI for routine assessment of early patient response to cancer treatment at the cellular level. The POLARIS system utilizes hyperpolarization technology to amplify the MRI signal of natural metabolites by over 10,000x, making them detectable with existing MRI equipment. This allows clinicians to identify resistant versus sensitive tumors within days of treatment, facilitating informed decisions about therapy adjustments. The platform offers a robust and easy-to-use workflow with high throughput and convenient, room-temperature processing.
Target Audience
The primary target audience includes preclinical and clinical researchers, as well as medical professionals in oncology, cardiology, and other fields who require early and accurate assessment of treatment response at the metabolic level.
Features
- POLARIS hyperpolarization system for rapid enhancement of MRI signals from metabolic agents
- Compatibility with standard MRI systems, eliminating the need for specialized equipment
- High-throughput processing, achieving polarization in approximately 3 minutes per dose
- Room-temperature operation, simplifying workflow and reducing infrastructure requirements
- Capability to detect early metabolic changes at the cellular level, days after treatment onset
- Applications across oncology, cardiology, hepatology, nephrology, neurology, and rheumatology